Ibakin 100 mg (Tablet)

Unit Price: ৳ 100.00 (3 x 10: ৳ 3,000.00)

Strip Price: ৳ 1,000.00

Medicine Details

Treats newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in adults and pediatric patients
Effective for Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after interferon-alpha therapy failure
Used for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia in adults
Treatment for hypereosinophilic syndrome and/or chronic eosinophilic leukemia with FIP1L1-PDGFR a fusion kinase
Indicated for unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans
Appropriate for patients with aggressive systemic mastocytosis without the D816V c-Kit mutation
Adjuvant treatment post-complete gross resection of Kit positive gastrointestinal stromal tumors
Suitable for pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia
Treats myelodysplastic/myeloproliferative diseases associated with platelet-derived growth factor receptor gene rearrangements
Effective for patients with Kit positive unresectable and/or metastatic malignant gastrointestinal stromal tumors

A small molecule protein-tyrosine kinase inhibitor
Potently inhibits the activity of the Bcr-Abl tyrosine kinase and several receptor tyrosine kinases
Inhibits cellular events mediated by activation of receptor kinases
Well absorbed after oral administration with Cmax achieved within 2-4 hours post-dose
Mean absolute bioavailability is 98%
Metabolized by CYP3A4 with minor role played by other cytochrome P450 enzymes
Predominantly excreted in feces, mostly as metabolites
Elimination half-lives of Imatinib and its major active metabolite are approximately 18 and 40 hours, respectively

400 mg/day for adults with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase
600 mg/day for adults with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase or blast crisis
340 mg/m2/day for pediatrics with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase
600 mg/day for adults with Philadelphia chromosome positive acute lymphoblastic leukemia
340 mg/m2/day for pediatrics with Philadelphia chromosome positive acute lymphoblastic leukemia
400 mg/day for adults with myelodysplastic/myeloproliferative diseases
100 mg/day or 400 mg/day for adults with aggressive systemic mastocytosis
100 mg/day or 400 mg/day for adults with hypereosinophilic syndrome and/or chronic eosinophilic leukemia
800 mg/day for adults with unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans
400 mg/day for patients with Kit positive unresectable and/or metastatic malignant gastrointestinal stromal tumors
400 mg/day for adjuvant treatment of adults following complete gross resection of Kit positive gastrointestinal stromal tumors
Doses should be taken with food and a large glass of water

Concomitant administration with CYP3A4 inducers may reduce total exposure of imatinib
Concomitant administration with CYP3A4 inhibitors may result in significant imatinib exposure increase
Potential increase in plasma concentrations of drugs metabolized by CYP3A4
Use caution when administering with CYP3A4 substrates that have a narrow therapeutic window
Use caution when administering with CYP2D6 substrates that have a narrow therapeutic window

Women of childbearing potential must use effective contraception during treatment and for at least 15 days after stopping treatment
Limited data on the use of imatinib in pregnant women, with potential risk to the fetus
Limited information on imatinib distribution in human milk, caution advised for breastfeeding
Effects on fertility and gametogenesis have not been fully studied